Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer

$10 USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	University of Georgia
Country	United States
Start Date	Sep 01, 2023
End Date	Aug 31, 2027
Duration	1,460 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10928807`

Grant Description

PROJECT SUMMARY: For women in the United States, breast cancer is the most common malignancy and the second leading cause of death. In this application, we focus upon a specific subtype of breast cancer known as triple-negative breast cancer (TNBC). Compared to other breast cancer subtypes, TNBC is considered more aggressive and extremely

difficult to treat with standard therapies. As a result, it has a high recurrence rate and a high overall mortality rate. TNBC accounts for up to 20% of all breast cancers, with a higher incidence in ethnic minority populations and young women (usually